drugset / Trial / NCT00293345

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00293345

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma. Drugs used in chemotherapy, such as 3-AP and gemcitabine (GEM), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. 3-AP may help gemcitabine kill more cancer cells by making the cells more sensitive to the drug. 3-AP may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2006-06
Primary completion
2012-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Triapine Small molecule Intravenous
Background Gemcitabine Small molecule Intravenous